AnaptysBio (ANAB) Projected to Post Earnings on Monday

Key Points

• AnaptysBio is set to release its Q2 2025 earnings before market opens on August 4th, with expected earnings of ($1.47) per share and revenue of $11.55 million.
($1.28), exceeding estimates and generating $27.77 million in revenue, compared to a consensus estimate of $15.27 million.
• Several brokerage firms have increased their price targets for AnaptysBio, with Guggenheim raising it to $90.00 and JPMorgan increasing theirs to $80.00, indicating strong analyst confidence in the stock.

AnaptysBio (NASDAQ:ANAB - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect AnaptysBio to post earnings of ($1.47) per share and revenue of $11.55 million for the quarter.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.30) by $0.02. The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative return on equity of 282.47% and a negative net margin of 125.70%. On average, analysts expect AnaptysBio to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

AnaptysBio Stock Performance

Shares of NASDAQ:ANAB traded down $0.16 during mid-day trading on Thursday, hitting $24.83. 249,010 shares of the company traded hands, compared to its average volume of 789,547. The firm has a market cap of $729.36 million, a P/E ratio of -5.12 and a beta of -0.27. AnaptysBio has a 52-week low of $12.21 and a 52-week high of $41.31. The firm's 50 day simple moving average is $23.92 and its 200 day simple moving average is $20.08.

Insider Activity at AnaptysBio

In other news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the sale, the director owned 4,965 shares of the company's stock, valued at approximately $117,025.05. The trade was a 80.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 33.50% of the company's stock.

Institutional Trading of AnaptysBio

An institutional investor recently raised its position in AnaptysBio stock. AQR Capital Management LLC increased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 153.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,011 shares of the biotechnology company's stock after buying an additional 18,165 shares during the quarter. AQR Capital Management LLC owned 0.10% of AnaptysBio worth $558,000 as of its most recent filing with the Securities and Exchange Commission.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Wedbush reiterated an "outperform" rating and issued a $40.00 target price on shares of AnaptysBio in a research report on Thursday, May 29th. Guggenheim reiterated a "buy" rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. Finally, HC Wainwright upgraded AnaptysBio from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $47.13.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.